Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | EPM2A | O95278 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133259 | 0.85 | CHRM2 (0.45) | CA2CA12CYP2A6HTR1BPTGS2 | |
| SCHEMBL3796719 | 0.81 | CYP2A6 (0.47) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL17955745 | 0.81 | CYP2A6 (0.47) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL692366 | 0.81 | CYP2A6 (0.47) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL9075377 | 0.81 | CA2 (0.51) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL23841198 | 0.80 | CA2 (0.45) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL3793838 | 0.80 | CA2 (0.51) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL12597507 | 0.80 | CA2 (0.45) | CA2CA12CYP2A6EPM2APTPRC | |
| SCHEMBL12468448 | 0.80 | CA2 (0.55) | CA2CA12CYP2A6DYRK1A | |
| Hydrochloric Acid SCHEMBL27827959 | 0.79 | CYP2A6 (0.46) | CA2CA12CYP2A6EPM2APTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| WO-2021202796-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20200165519-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2020-05-28 | — | — | US | disclosed |
| WO-2020061255-A1 | ACTIVATING PYRUVATE KINASE R | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190276744-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-09-12 | — | — | US | disclosed |
| US-10336938-B2 | Liquid crystal composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20170306234-A1 | LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170283700-A1 | LIQUID CRYSTAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-05 | — | — | US | disclosed |
| US-9403789-B2 | Benzofuran-containing amino acid inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-8389571-B2 | Benzofuran derived HIV protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110281824-A1 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7981929-B2 | Resistance-repellent and multidrug resistant retroviral protease inhibitors; cytochrome P450 inhibitor | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080227744-A1 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | CA2 4318/4885CA12 3663/4885CYP2A6 4409/4885 |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | CA2 4340/4885CA12 4259/4885CYP2A6 1232/4885 |
| US-20080227744-A1 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS | SERPINB1, PREP, PRSS1 | CA2 4376/4885CA12 4702/4885CYP2A6 1661/4885 |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SERPINB1, MMP7, MME | CA2 4412/4885CA12 4388/4885CYP2A6 2831/4885 |
| US-20110281824-A1 | BENZOFURAN DERIVED HIV PROTEASE INHIBITORS | SERPINB1, PREP, PRSS1 | CA2 4376/4885CA12 4702/4885CYP2A6 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.